




RealRate

PHARMACEUTICAL 2025

Adial Pharmaceuticals INC
Rank 184 of 225



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Adial Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Adial Pharmaceuticals INC compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 27% points. The greatest weakness of Adial Pharmaceuticals INC is the variable Net Income, reducing the Economic Capital Ratio by 146% points.

The company's Economic Capital Ratio, given in the ranking table, is 120%, being 95% points below the market average of 215%.

Input Variable	Value in 1000 USD
Assets, Current	4,059
Cost of Goods Sold	0
Intangible Assets	3.3
Liabilities, Current	976
Liabilities, Non-Current	0
Other Assets	982
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	-4,913
Other Revenues	0
Property and Equipment	0
Research and Development	3,229
Selling, General and Administrative Expense	5,055

Output Variable	Value in 1000 USD
Assets	5,044
Liabilities	976
Expenses	8,284
Revenues	0
Stockholders Equity	4,068
Net Income	-13,197
Comprehensive Net Income	-13,197
BaseVar	9,609
ECR before LimitedLiability	-144%
Economic Capital Ratio	120%